Connection
Satish Garg to Adult
This is a "connection" page, showing publications Satish Garg has written about Adult.
|
|
Connection Strength |
|
 |
|
 |
|
1.545 |
|
|
|
-
Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 Jun; 27(6):430-438.
Score: 0.049
-
Garg SK, Kaur G, Renner D, Lanning MS, Mason E, Beatson C, Ciesco K, Snell-Bergeon J. Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther. 2025 Mar; 27(3):152-160.
Score: 0.049
-
Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Jan; 27(1):1-9.
Score: 0.048
-
Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. 2024 Nov; 26(11):5202-5210.
Score: 0.047
-
Boeder S, Davies MJ, McGill JB, Pratley R, Girard M, Banks P, Pettus J, Garg S. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technol Ther. 2024 Sep; 26(9):618-625.
Score: 0.046
-
Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 Jun; 26(6):367-374.
Score: 0.046
-
Bailey R, Calhoun P, Garg SK. Weight Gain and Glycemic Control in Adults with Type 1 Diabetes in the T1D Exchange Registry. Diabetes Technol Ther. 2024 Mar; 26(3):156-160.
Score: 0.045
-
Garg SK, Grunberger G, Weinstock R, Lawson ML, Hirsch IB, DiMeglio LA, Pop-Busui R, Philis-Tsimikas A, Kipnes M, Liljenquist DR, Brazg RL, Kudva YC, Buckingham BA, McGill JB, Carlson AL, Criego AB, Christiansen MP, Kaiserman KB, Griffin KJ, Forlenza GP, Bode BW, Slover RH, Keiter A, Ling C, Marinos B, Cordero TL, Shin J, Lee SW, Rhinehart AS, Vigersky RA. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial. Diabetes Technol Ther. 2023 01; 25(1):1-12.
Score: 0.042
-
Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 06; 24(6):373-380.
Score: 0.039
-
Peters AL, Garg SK. The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth. Diabetes Technol Ther. 2020 Jun; 22(6):449-453.
Score: 0.035
-
Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Mukherjee B, Shah VN. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020 02; 22(2):85-95.
Score: 0.034
-
Thrasher J, Polsky S, Hovsepian L, Nowotny I, Pierre S, Bois De Fer B, Bhargava A, Mukherjee B, Garg SK. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial. Diabetes Technol Ther. 2020 09; 22(9):666-673.
Score: 0.034
-
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer SA, Bonnemaire M, Sawhney S, Stewart J, Wang S, Castro RC, Garg SK. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2019 09; 21(9):471-477.
Score: 0.033
-
Garg SK, Shah V. Closed-loop insulin delivery systems for patients with diabetes. Lancet Digit Health. 2019 05; 1(1):e2-e3.
Score: 0.032
-
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 02; 21(2):66-72.
Score: 0.032
-
Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
Score: 0.031
-
Akturk HK, Rewers A, Garg SK. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018 08; 25(4):246-250.
Score: 0.031
-
Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018 06; 20(6):395-402.
Score: 0.031
-
Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technol Ther. 2018 06; 20(6):428-433.
Score: 0.030
-
Home P, Derwahl KM, Ziemen M, Wernicke-Panten K, Pierre S, Kirchhein Y, Garg SK. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. Diabetes Technol Ther. 2018 02; 20(2):160-170.
Score: 0.030
-
Thrasher J, Surks H, Nowotny I, Pierre S, Rotthaeuser B, Wernicke-Panten K, Garg S. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. J Diabetes Sci Technol. 2018 05; 12(3):680-686.
Score: 0.030
-
Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Sim? R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017 12 14; 377(24):2337-2348.
Score: 0.029
-
Garg SK, Wernicke-Panten K, Rojeski M, Pierre S, Kirchhein Y, Jedynasty K. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study. Diabetes Technol Ther. 2017 09; 19(9):516-526.
Score: 0.029
-
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2017 03; 19(3):155-163.
Score: 0.028
-
Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2016 Feb; 18 Suppl 1:S3-9.
Score: 0.026
-
Garg SK, Admane K, Freemantle N, Odawara M, Pan CY, Misra A, Jarek-Martynowa IR, Abbas-Raza S, Mirasol RC, Perfetti R. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015 Feb; 21(2):143-57.
Score: 0.024
-
Garg SK, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR. Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. Diabetes Technol Ther. 2014 Mar; 16(3):125-30.
Score: 0.022
-
Ahmann A, Szeinbach SL, Gill J, Traylor L, Garg SK. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. Diabetes Technol Ther. 2014 Feb; 16(2):76-83.
Score: 0.022
-
Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013 Jan-Feb; 19(1):19-28.
Score: 0.021
-
Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther. 2012 Mar; 14(3):205-9.
Score: 0.020
-
Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011 Nov-Dec; 17(6):845-52.
Score: 0.019
-
Garg SK, Voelmle MK, Beatson CR, Miller HA, Crew LB, Freson BJ, Hazenfield RM. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care. 2011 Mar; 34(3):574-9.
Score: 0.018
-
Garg S, Moser E, Dain MP, Rodionova A. Clinical experience with insulin glargine in type 1 diabetes. Diabetes Technol Ther. 2010 Nov; 12(11):835-46.
Score: 0.018
-
Garg SK, Voelmle M, Gottlieb PA. Time lag characterization of two continuous glucose monitoring systems. Diabetes Res Clin Pract. 2010 Mar; 87(3):348-53.
Score: 0.017
-
Rodbard D, Jovanovic L, Garg SK. Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections. Diabetes Technol Ther. 2009 Dec; 11(12):757-65.
Score: 0.017
-
Garg SK, Mathieu C, Rais N, Gao H, Tobian JA, Gates JR, Ferguson JA, Webb DM, Berclaz PY. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. Diabetes Technol Ther. 2009 Sep; 11 Suppl 2:S5-S16.
Score: 0.017
-
Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther. 2009 Feb; 11(2):65-72.
Score: 0.016
-
Garg SK, Voelmle MK, Gottlieb P. Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes. Diabetes Care. 2009 Mar; 32(3):436-8.
Score: 0.016
-
Garg SK, Bookout TR, McFann KK, Kelly WC, Beatson C, Ellis SL, Gutin RS, Gottlieb PA. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther. 2008 Oct; 10(5):369-75.
Score: 0.016
-
Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK, Ellis SL. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007 Dec; 30(12):3023-5.
Score: 0.015
-
Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007 Jun; 9(3):203-10.
Score: 0.014
-
Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan; 29(1):44-50.
Score: 0.013
-
Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, Rewers MJ, Garg SK. Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care. 2005 Mar; 28(3):714-5.
Score: 0.012
-
Garg SK, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract. 2005 Jan-Feb; 11(1):11-7.
Score: 0.012
-
Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004 Oct; 66(1):49-56.
Score: 0.012
-
Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004 Oct; 6(5):589-95.
Score: 0.012
-
Garg SK, Carter JA, Mullen L, Folker AC, Parkes JL, Tideman AM. The clinical performance and ease of use of a blood glucose meter that uses a 10-test disk. Diabetes Technol Ther. 2004 Aug; 6(4):495-502.
Score: 0.012
-
Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004 Mar; 27(3):734-8.
Score: 0.011
-
Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther. 2004 Feb; 6(1):9-15.
Score: 0.011
-
Chase HP, Pearson JA, Wightman C, Roberts MD, Oderberg AD, Garg SK. Modem transmission of glucose values reduces the costs and need for clinic visits. Diabetes Care. 2003 May; 26(5):1475-9.
Score: 0.011
-
Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr Pract. 2003 May-Jun; 9(3):187-93.
Score: 0.011
-
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 10; 28(10):2092-2099.
Score: 0.010
-
Brazg R, Garg SK, Bhargava A, Thrasher JR, Latif K, Bode BW, Bailey TS, Horowitz BS, Cavale A, Kudva YC, Kaiserman KB, Grunberger G, Reed JC, Chattaraj S, Zhang G, Shin J, Chen V, Lee SW, Cordero TL, Rhinehart AS, Vigersky RA, Buckingham BA. Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial. Diabetes Technol Ther. 2022 08; 24(8):535-543.
Score: 0.010
-
Johnston-Brooks CH, Lewis MA, Garg S. Self-efficacy impacts self-care and HbA1c in young adults with Type I diabetes. Psychosom Med. 2002 Jan-Feb; 64(1):43-51.
Score: 0.010
-
Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMed? Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 03; 24(3):178-189.
Score: 0.010
-
Akturk HK, Snell-Bergeon J, Pyle L, Fivekiller E, Garg S, Cobry E. Accuracy of a breath ketone analyzer to detect ketosis in adults and children with type 1 diabetes. J Diabetes Complications. 2021 11; 35(11):108030.
Score: 0.010
-
Rodbard HW, Giaccari A, Cariou B, Garg S, Davies MJ, Seth K, Sawhney S. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diab Vasc Dis Res. 2021 Jan-Feb; 18(1):1479164121995928.
Score: 0.009
-
Kelly CB, Wagner CL, Shary JR, Leyva MJ, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Hammad SM, Aston CE, Lyons TJ. Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes. Nutrients. 2020 Jul 10; 12(7).
Score: 0.009
-
DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. J Clin Endocrinol Metab. 2020 02 01; 105(2).
Score: 0.009
-
Kelly CB, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Basu A, Hammad SM, Aston CE, Lyons TJ. Haptoglobin Phenotype Modulates Lipoprotein-Associated Risk for Preeclampsia in Women With Type 1 Diabetes. J Clin Endocrinol Metab. 2019 10 01; 104(10):4743-4755.
Score: 0.008
-
Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019 05; 42(5):919-930.
Score: 0.008
-
Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care. 2018 Sep; 41(9):1970-1980.
Score: 0.008
-
Bjornstad P, Maahs DM, Roncal CA, Snell-Bergeon JK, Shah VN, Milagres T, Ellis SL, Hatch M, Chung LT, Rewers MJ, Garg S, Cherney DZ, Pyle L, Nadeau KJ, Johnson RJ. Role of bicarbonate supplementation on urine uric acid crystals and diabetic tubulopathy in adults with type 1 diabetes. Diabetes Obes Metab. 2018 07; 20(7):1776-1780.
Score: 0.008
-
Cordero TL, Garg SK, Brazg R, Bailey TS, Shin J, Lee SW, Kaufman FR. The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed? 670G Hybrid Closed-Loop System. Diabetes Technol Ther. 2017 Dec; 19(12):749-752.
Score: 0.007
-
Kelly CB, Hookham MB, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Garg SK, Scardo JA, Hammad SM, Menard MK, Aston CE, Lyons TJ. Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):120-127.
Score: 0.007
-
Kelly CB, Hookham MB, Yu JY, Lockhart SM, Du M, Jenkins AJ, Nankervis A, Hanssen KF, Henriksen T, Garg SK, Hammad SM, Scardo JA, Aston CE, Patterson CC, Lyons TJ. Circulating adipokines are associated with pre-eclampsia in women with type 1 diabetes. Diabetologia. 2017 12; 60(12):2514-2524.
Score: 0.007
-
Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR. Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor. Diabetes Technol Ther. 2017 08; 19(8):446-456.
Score: 0.007
-
Buckingham BA, Bailey TS, Christiansen M, Garg S, Weinzimer S, Bode B, Anderson SM, Brazg R, Ly TT, Kaufman FR. Evaluation of a Predictive Low-Glucose Management System In-Clinic. Diabetes Technol Ther. 2017 05; 19(5):288-292.
Score: 0.007
-
Sussman M, Sierra JA, Garg S, Bode B, Friedman M, Gill M, Kaufman F, Vigersky R, Menzin J. Economic impact of hypoglycemia among insulin-treated patients with diabetes. J Med Econ. 2016 Nov; 19(11):1099-1106.
Score: 0.007
-
Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015 Jul; 38(7):1181-8.
Score: 0.006
-
Weiss R, Garg SK, Bode BW, Bailey TS, Ahmann AJ, Schultz KA, Welsh JB, Shin JJ. Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study. Diabetes Technol Ther. 2015 Aug; 17(8):542-7.
Score: 0.006
-
Basu A, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, Henriksen T, Lorentzen B, Garg SK, Menard MK, Hammad SM, Scardo JA, Aston CE, Lyons TJ. Trace elements as predictors of preeclampsia in type 1 diabetic pregnancy. Nutr Res. 2015 May; 35(5):421-30.
Score: 0.006
-
Bailey TS, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, Welsh JB, Lee SW. Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. Diabetes Technol Ther. 2014 May; 16(5):277-83.
Score: 0.006
-
Klonoff DC, Bergenstal RM, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann A, Welsh JB, Lee SW. ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. J Diabetes Sci Technol. 2013 Jul 01; 7(4):1005-10.
Score: 0.005
-
Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013 Jul 18; 369(3):224-32.
Score: 0.005
-
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21; 379(9825):1489-97.
Score: 0.005
-
Basu A, Alaupovic P, Wu M, Jenkins AJ, Yu Y, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, Lorentzen B, Clausen T, Garg SK, Menard MK, Hammad SM, Scardo JA, Stanley JR, Dashti A, Aston CE, Lyons TJ. Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study. J Clin Endocrinol Metab. 2012 May; 97(5):1752-62.
Score: 0.005
-
Brazg RL, Bailey TS, Garg S, Buckingham BA, Slover RH, Klonoff DC, Nguyen X, Shin J, Welsh JB, Lee SW. The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol. 2011 Nov 01; 5(6):1466-71.
Score: 0.005
-
Young KA, Snell-Bergeon JK, Naik RG, Hokanson JE, Tarullo D, Gottlieb PA, Garg SK, Rewers M. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care. 2011 Feb; 34(2):454-8.
Score: 0.005
-
Maahs DM, Snell-Bergeon JK, Kinney GL, Wadwa RP, Garg S, Ogden LG, Rewers M. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. J Diabetes Complications. 2007 Sep-Oct; 21(5):273-9.
Score: 0.004
-
Kretowski A, McFann K, Hokanson JE, Maahs D, Kinney G, Snell-Bergeon JK, Wadwa RP, Eckel RH, Ogden L, Garg S, Li J, Cheng S, Erlich HA, Rewers M. Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosis. Diabetes. 2007 Mar; 56(3):863-71.
Score: 0.003
-
Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95.
Score: 0.003
-
Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Hokanson JE, Garg SK, Eckel RH, Rewers M. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care. 2005 May; 28(5):1051-6.
Score: 0.003
-
Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005 Mar; 28(3):533-8.
Score: 0.003
-
Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005 Feb; 28(2):301-6.
Score: 0.003
-
Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003 Nov; 52(11):2833-9.
Score: 0.003
-
Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care. 2003 Oct; 26(10):2923-8.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|